Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609334 | 1.00 | BACE1 (0.35) | BACE1CASRCYP2D6MEN1KMT2A | |
| SCHEMBL14502747 | 1.00 | BACE1 (0.35) | BACE1CASRCYP2D6MEN1KMT2A | |
| SCHEMBL14502746 | 1.00 | BACE1 (0.35) | BACE1CASRCYP2D6MEN1KMT2A | |
| SCHEMBL4609571 | 0.77 | BACE1 (0.40) | BACE1CASRCYP2D6HIF1A | |
| SCHEMBL4609733 | 0.77 | BACE1 (0.40) | BACE1CASRCYP2D6HIF1A | |
| SCHEMBL4609574 | 0.77 | BACE1 (0.40) | BACE1CASRCYP2D6HIF1A | |
| SCHEMBL4609594 | 0.76 | ALDH1A1 (0.47) | CASRCYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL14502702 | 0.76 | ALDH1A1 (0.47) | CASRCYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL4609592 | 0.76 | ALDH1A1 (0.47) | CASRCYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL4610221 | 0.74 | ALDH1A1 (0.45) | CASRCYP2D6MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308436-B1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-6916956-B2 | Calcium receptor antagonist | JAPAN TOBACCO, INC. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050107448-A1 | Calcium receptor antagonists | JAPAN TABACCO INC. | 2005-05-19 | — | — | US | disclosed |
| US-20040006130-A1 | Calcium receptor antagonist | JAPAN TOBACCO INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308436-A1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107448-A1 | Calcium receptor antagonists | CASR, CALCR, CALCRL | BACE1 1170/4885CASR 1/4885CYP2D6 497/4885 |
| US-20040006130-A1 | Calcium receptor antagonist | CALCRL, CASR, CALCR | BACE1 1227/4885CASR 2/4885CYP2D6 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.